Cargando…

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations

The anaplastic lymphoma kinase (ALK) rearrangement defines a distinct molecular subtype of non‐small cell lung cancer (NSCLC). Despite the excellent initial efficacy of ALK inhibitors in patients with ALK+ lung cancer, resistance occurs almost inevitably. To date, there is no reliable biomarker allo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alidousty, Christina, Baar, Till, Martelotto, Luciano G, Heydt, Carina, Wagener, Svenja, Fassunke, Jana, Duerbaum, Nicolai, Scheel, Andreas H, Frank, Sandra, Holz, Barbara, Binot, Elke, Kron, Anna, Merkelbach‐Bruse, Sabine, Ihle, Michaela A, Wolf, Jürgen, Buettner, Reinhard, Schultheis, Anne Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2018
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120547/ https://www.ncbi.nlm.nih.gov/pubmed/29885057 http://dx.doi.org/10.1002/path.5110

Ejemplares similares

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
por: Castiglione, Roberta, et al.
Publicado: (2018)

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
por: Kron, A, et al.
Publicado: (2018)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy
por: Heydt, Carina, et al.
Publicado: (2015)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics
por: Heydt, Carina, et al.
Publicado: (2014)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer
por: Thangarajah, Fabinshy, et al.
Publicado: (2023)

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
por: Gamerith, Gabriele, et al.
Publicado: (2022)

Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2017)

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
por: FASSUNKE, JANA, et al.
Publicado: (2015)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
por: Heydt, Carina, et al.
Publicado: (2021)

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
por: Fassunke, Jana, et al.
Publicado: (2010)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
por: Scheffler, Matthias, et al.
Publicado: (2014)

c-myc copy number gain is a powerful prognosticator of disease outcome in cervical dysplasia
por: Kübler, Kirsten, et al.
Publicado: (2014)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study
por: Koitzsch, Ulrike, et al.
Publicado: (2017)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
por: Quaas, Alexander, et al.
Publicado: (2019)

A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
por: Huss, Sebastian, et al.
Publicado: (2013)

Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies
por: Klein, Sebastian, et al.
Publicado: (2020)

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
por: Angelika Ihle, Michaela, et al.
Publicado: (2016)

Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
por: Heydt, Carina, et al.
Publicado: (2020)

Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
por: Quaas, A., et al.
Publicado: (2018)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Biomarker MET in der Tumorpathologie
por: Ihle, Michaela Angelika, et al.
Publicado: (2023)

hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions
por: Silva, Tanielly Cristina Raiol, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fs64ek17ls530qkeg5hf146fjq